CA2174236A1 - Superoxide dismutase and mimetics thereof - Google Patents

Superoxide dismutase and mimetics thereof

Info

Publication number
CA2174236A1
CA2174236A1 CA002174236A CA2174236A CA2174236A1 CA 2174236 A1 CA2174236 A1 CA 2174236A1 CA 002174236 A CA002174236 A CA 002174236A CA 2174236 A CA2174236 A CA 2174236A CA 2174236 A1 CA2174236 A1 CA 2174236A1
Authority
CA
Canada
Prior art keywords
mimetics
superoxide dismutase
relates
radicals
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002174236A
Other languages
French (fr)
Other versions
CA2174236C (en
Inventor
James D. Crapo
Irwin Fridovich
Tim Oury
Brian J. Day
Rodney J. Folz
Bruce A. Freeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Duke University
Original Assignee
James D. Crapo
Irwin Fridovich
Tim Oury
Brian J. Day
Rodney J. Folz
Bruce A. Freeman
Duke University
University Of Alabama At Birmingham Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James D. Crapo, Irwin Fridovich, Tim Oury, Brian J. Day, Rodney J. Folz, Bruce A. Freeman, Duke University, University Of Alabama At Birmingham Research Foundation filed Critical James D. Crapo
Priority to CA002614621A priority Critical patent/CA2614621A1/en
Publication of CA2174236A1 publication Critical patent/CA2174236A1/en
Application granted granted Critical
Publication of CA2174236C publication Critical patent/CA2174236C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0089Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • A61K47/546Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating intra- and extracellular levels of superoxide radicals and thereby processes in which such radicals are a participant.
The invention also relates to compounds and compositions suitable for use in such methods.
CA002174236A 1993-10-15 1994-10-13 Superoxide dismutase and mimetics thereof Expired - Lifetime CA2174236C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002614621A CA2614621A1 (en) 1993-10-15 1994-10-13 Superoxide dismutase and mimetics thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13620793A 1993-10-15 1993-10-15
US136,207 1993-10-15
PCT/US1994/011558 WO1995010185A1 (en) 1993-10-15 1994-10-13 Superoxide dismutase and mimetics thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002614621A Division CA2614621A1 (en) 1993-10-15 1994-10-13 Superoxide dismutase and mimetics thereof

Publications (2)

Publication Number Publication Date
CA2174236A1 true CA2174236A1 (en) 1995-04-20
CA2174236C CA2174236C (en) 2008-02-12

Family

ID=22471830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002174236A Expired - Lifetime CA2174236C (en) 1993-10-15 1994-10-13 Superoxide dismutase and mimetics thereof

Country Status (9)

Country Link
US (1) US5747026A (en)
EP (2) EP1442747A1 (en)
JP (1) JPH09505805A (en)
AT (1) ATE291351T1 (en)
AU (1) AU702596B2 (en)
CA (1) CA2174236C (en)
DE (1) DE69434313T2 (en)
ES (1) ES2237753T3 (en)
WO (1) WO1995010185A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
AU3758695A (en) * 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
ES2249784T3 (en) * 1995-06-07 2006-04-01 Duke University ANTIOXIDANTGES OF OXIDANTS.
CA2229781A1 (en) * 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
CA2183834C (en) * 1995-08-22 2003-09-09 Hiroshi Maeda Antihypertensive agents containing pyrazolopyrimidine derivatives
IL125889A0 (en) * 1996-03-13 1999-04-11 Monsanto Co Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
ATE238307T1 (en) * 1997-11-03 2003-05-15 Univ Duke SUBSTITUTED PORPHYRINS
US6479477B1 (en) 1998-04-24 2002-11-12 Duke University Substituted porphyrins
WO2000009111A2 (en) * 1998-08-11 2000-02-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibitors of amyloid formation
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
US6210392B1 (en) * 1999-01-15 2001-04-03 Interventional Technologies, Inc. Method for treating a wall of a blood vessel
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
ATE552260T1 (en) * 1999-01-25 2012-04-15 Nat Jewish Health SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE
IT1306716B1 (en) * 1999-06-21 2001-10-02 Mendes S U R L ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES.
SE9903985D0 (en) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
FR2806911B1 (en) * 2000-03-28 2003-01-10 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
EP1367998A4 (en) * 2000-09-15 2004-03-17 Scripps Research Inst Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
ATE439134T1 (en) * 2001-01-19 2009-08-15 Nat Jewish Med & Res Center MEDICINE FOR PROTECTION IN RADIOTHERAPY
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
JP2005508864A (en) * 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター Oxidant scavengers for the treatment of diabetes or for use in transplantation or for induction of immune tolerance
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20050129680A1 (en) * 2001-09-17 2005-06-16 Paul Wentworth Antimicrobial activity of antibodies
US20040157280A1 (en) * 2001-09-17 2004-08-12 Paul Wentworth Antibody mediated ozone generation
AU2003216400A1 (en) 2002-02-22 2003-09-09 The Curators Of The University Of Missouri Compounds for treatment of copper overload
CA2488500A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
JP2006506613A (en) * 2002-11-14 2006-02-23 ノバルティス アクチエンゲゼルシャフト Ozone production via antibodies or neutrophils
DK2604621T3 (en) 2003-05-01 2016-02-01 Cornell Res Foundation Inc Process and carrier complexes for delivering molecules to cells.
CA2561266A1 (en) 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US8697120B2 (en) * 2006-05-01 2014-04-15 Johns Hopkins University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
CN102088991A (en) 2008-05-13 2011-06-08 堪萨斯大学 Metal abstraction peptide (MAP) tag and associated methods
ES2464728T3 (en) 2008-05-23 2014-06-03 National Jewish Health Compounds for use in the treatment of lesions associated with exposure to an alkylating chemical species
JP4891367B2 (en) 2009-05-21 2012-03-07 トヨタ自動車株式会社 Solvent composition
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CN104190927B (en) 2014-08-11 2016-05-18 苏州大学 A kind of synchronous powder feeding system space laser processing and three-dimensional method and device

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4758422A (en) * 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
EP0223831B1 (en) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
DK402785D0 (en) * 1985-09-03 1985-09-03 Syn Tek Ab PROCEDURE FOR THE PREPARATION OF AN ENZYM
DE3854872D1 (en) * 1987-03-14 1996-02-22 Boehringer Ingelheim Int Human manganese superoxide dismutase (hMn-SOD)
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5171680A (en) * 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
WO1990010694A1 (en) * 1989-03-06 1990-09-20 Suntory Limited New superoxide dismutase
DK455789D0 (en) * 1989-09-15 1989-09-15 Symbicom Ab POLYPEPTIDE
EP0424033A3 (en) * 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
EP0462836A3 (en) * 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5202317A (en) * 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5217966A (en) * 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
DE69224839T2 (en) * 1991-07-19 1998-10-08 Monsanto Co Manganese complexes with nitrogen-containing macrocyclic ligands, effective as superoxide dismutase catalysts.
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
ATE552260T1 (en) * 1999-01-25 2012-04-15 Nat Jewish Health SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof

Also Published As

Publication number Publication date
JPH09505805A (en) 1997-06-10
EP0723398A4 (en) 1999-03-24
AU7976394A (en) 1995-05-04
EP1442747A1 (en) 2004-08-04
EP0723398B1 (en) 2005-03-23
WO1995010185A1 (en) 1995-04-20
DE69434313T2 (en) 2006-03-30
EP0723398A1 (en) 1996-07-31
AU702596B2 (en) 1999-02-25
CA2174236C (en) 2008-02-12
ATE291351T1 (en) 2005-04-15
US5747026A (en) 1998-05-05
DE69434313D1 (en) 2005-04-28
ES2237753T3 (en) 2005-08-01

Similar Documents

Publication Publication Date Title
CA2174236A1 (en) Superoxide dismutase and mimetics thereof
CA2224173A1 (en) Sunscreen compositions
IL135949A0 (en) Substituted porphyrins
CA2172513A1 (en) Aminocyclohexylesters and uses thereof
CA2228752A1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
CA2054590A1 (en) Novel cyclosporins
CA2218090A1 (en) Cleansing emulsions
IL122451A0 (en) Oxidant scavengers
CA2374442A1 (en) Silicone gel containing salicylic acid
CA2182158A1 (en) Detergents and cleaners containing iminodisuccinates
CA2223510A1 (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
BG104392A (en) Methods for the modulation of serin/treonin protein kinase function with compounds based on 5-azaquinoxaline
CA2163361A1 (en) Therapeutic substituted guanidines
EP1071474A4 (en) Substituted porphyrins
CA2102241A1 (en) Use of macrolide compounds for eye diseases
CA2199844A1 (en) Compositions for the treatment of skin disorders
CA2218289A1 (en) Cd45rb binding compounds for the prevention of transplant rejection
WO1996021468A3 (en) Chemically modified interferon
CA2180846A1 (en) Method of treating disorders of the eye
AU6682594A (en) Treatment of septic shock
GR3033112T3 (en) Stabilised sunscreen compositions
CA2293808A1 (en) Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
WO1996031208A3 (en) Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
AU6021794A (en) Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
CA2171728A1 (en) Triaryl-ethylene derivatives for use in therapy

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141014